

INFORMATION LETTER
February 28th, 2021

Avifavir[®] has been registered recently in Russia by Chromis OOO¹ for treatment of novel coronavirus infection (COVID-19). Avifavir[®] has been included into the Ministry of Health's guidelines for the prevention, diagnosis and treatment of new coronavirus infection (COVID-19) in Russia.

Below is the brief information about Avifavir[®] medicinal product:

DRUG PRODUCT	Avifavir [®] (INN Favipiravir)
MARKETING AUTHORIZATION CERTIFICATE ²	# LP-006225-290520 Date 29.05.2020
ISSUED BY	MINISTRY OF HEALTH OF THE RUSSIAN FEDERATION
MARKETING AUTHORIZATION HOLDER	CHROMIS LLC, Russia Address: Building 1, 42 Bolshoy Boulevard, room 264, floor 0, territory of the Skolkovo Innovation center, Moscow, 121205 Russia
MANUFACTURING SITE	Chemical Diversity Research Institute (CDRI) JSC, Russia Address: Bldg. 1, 2A Rabochaya Str., Khimki city district, Khimki, Moscow Region, Russia
THERAPEUTIC GROUP	Antiviral agent
INDICATION	Treatment of novel coronavirus infection (COVID-19).
DOSAGE and ADMINISTRATION	Orally, 30 minutes before meal. Avifavir [®] is prescribed as inpatient treatment. Avifavir [®] is prescribed for adults according to the standard regimen depending on the patient's body weight. Total duration of treatment 10 days.
DOSAGE FORM / PACK SIZE	200 mg, Film-coated tablets / # 40
STORAGE CONDITIONS	At a temperature not higher than 25°C.
SHELF LIFE	1 year

In case if you are interested in ordering Avifavir[®] medicinal product please send your request with the following information:

- Company name, Country of Incorporation;
- Intended country for distribution of drug;
- Contact details of responsible person;
- Number of packs;
- Required time of delivery.

We will provide you then with terms of delivery and pricing info.

Please note that all the distribution rights for Avifavir[®] belong to ChemRar Group of Companies and OOO CHROMIS.

¹ Chromis LLC is a Joint Venture (JV) of the Russian Direct Investment Fund (RDIF), Russia's sovereign wealth fund, with ChemRar Group aimed at the production of Avifavir[®] and other related innovative antiviral medicines.

² Important notice: This pharmaceutical product is approved according to the registration procedure for the drugs intended for use in the state or preparedness of emergency. The use of the drug is possible only in inpatient care.